메뉴 건너뛰기




Volumn 22, Issue 7, 2008, Pages 1428-1430

Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; GENOMIC DNA; TRANSCRIPTION FACTOR GATA 1;

EID: 47549099019     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405060     Document Type: Letter
Times cited : (55)

References (15)
  • 1
    • 0342905433 scopus 로고    scopus 로고
    • Risks of leukaemia and solid tumours in individuals with Down's syndrome
    • Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 2000; 355 165-169.
    • (2000) Lancet , vol.355 , pp. 165-169
    • Hasle, H.1    Clemmensen, I.H.2    Mikkelsen, M.3
  • 2
    • 0035412104 scopus 로고    scopus 로고
    • Pattern of malignant disorders in individuals with Down's syndrome
    • Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 2001; 2: 429-436.
    • (2001) Lancet Oncol , vol.2 , pp. 429-436
    • Hasle, H.1
  • 3
    • 11144242549 scopus 로고    scopus 로고
    • Origins of leukaemia in children with Down syndrome
    • Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5: 11-20.
    • (2005) Nat Rev Cancer , vol.5 , pp. 11-20
    • Hitzler, J.K.1    Zipursky, A.2
  • 4
    • 27744567768 scopus 로고    scopus 로고
    • Optimizing therapy for myeloid disorders of Down syndrome
    • Webb DK. Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol 2005; 131: 3-7.
    • (2005) Br J Haematol , vol.131 , pp. 3-7
    • Webb, D.K.1
  • 5
    • 33646676254 scopus 로고    scopus 로고
    • Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and a review of the literature
    • Abildgaard L, Ellebæk E, Gustafsson G, Abrahamsson J, Hovi L, Jonmundsson G et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006; 85: 275-280.
    • (2006) Ann Hematol , vol.85 , pp. 275-280
    • Abildgaard, L.1    Ellebæk, E.2    Gustafsson, G.3    Abrahamsson, J.4    Hovi, L.5    Jonmundsson, G.6
  • 6
    • 33644905562 scopus 로고    scopus 로고
    • Treatment for myeloid leukaemia of Down syndrome: Population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials
    • Rao A, Hills RK, Stiller C, Gibson BE, De Graaf SS, Hann IM et al. Treatment for myeloid leukaemia of Down syndrome: Population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 2006; 132: 576-583.
    • (2006) Br J Haematol , vol.132 , pp. 576-583
    • Rao, A.1    Hills, R.K.2    Stiller, C.3    Gibson, B.E.4    De Graaf, S.S.5    Hann, I.M.6
  • 7
    • 0037325661 scopus 로고    scopus 로고
    • A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases
    • Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003; 17: 277-282.
    • (2003) Leukemia , vol.17 , pp. 277-282
    • Hasle, H.1    Niemeyer, C.M.2    Chessells, J.M.3    Baumann, I.4    Bennett, J.M.5    Kerndrup, G.6
  • 8
    • 0142089730 scopus 로고    scopus 로고
    • Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloidleukemia: A report from the Children's cancer group Study 2891
    • Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR et al Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloidleukemia: A report from the Children's cancer group Study 2891. J Clin Oncol 2003; 21: 3415-3422.
    • (2003) J Clin Oncol , vol.21 , pp. 3415-3422
    • Gamis, A.S.1    Woods, W.G.2    Alonzo, T.A.3    Buxton, A.4    Lange, B.5    Barnard, D.R.6
  • 9
    • 18944404989 scopus 로고    scopus 로고
    • AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity
    • Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355-1360.
    • (2005) Leukemia , vol.19 , pp. 1355-1360
    • Creutzig, U.1    Reinhardt, D.2    Diekamp, S.3    Dworzak, M.4    Stary, J.5    Zimmermann, M.6
  • 10
    • 16744366910 scopus 로고    scopus 로고
    • Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's cancer group studies 2861 and 2891
    • Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's cancer group studies 2861 and 2891. Blood 1998; 91 608-615.
    • (1998) Blood , vol.91 , pp. 608-615
    • Lange, B.J.1    Kobrinsky, N.2    Barnard, D.R.3    Arthur, D.C.4    Buckley, J.D.5    Howells, W.B.6
  • 11
    • 0031213812 scopus 로고    scopus 로고
    • Acute myeloblastic leukemia associated with trisomy 8 and translocation 8;21 in a child with Down syndrome
    • Yamaguchi Y, Fujii H, Kazama H, Iinuma K, Shinomiya N, Aoki T. Acute myeloblastic leukemia associated with trisomy 8 and translocation 8;21 in a child with Down syndrome. Cancer Genet Cytogenet 1997; 97 32-34.
    • (1997) Cancer Genet Cytogenet , vol.97 , pp. 32-34
    • Yamaguchi, Y.1    Fujii, H.2    Kazama, H.3    Iinuma, K.4    Shinomiya, N.5    Aoki, T.6
  • 12
    • 8044248968 scopus 로고    scopus 로고
    • Acute myelogenous leukaemia with t(8;21) translocation of normal cell origin in mosaic Down's syndrome with isochromosome 21 q
    • Sato A, Imaizumi M, Koizumi Y, Obara Y, Nakai H, Noro T et al. Acute myelogenous leukaemia with t(8;21) translocation of normal cell origin in mosaic Down's syndrome with isochromosome 21 q. Br J Haematol 1997; 96: 614-616.
    • (1997) Br J Haematol , vol.96 , pp. 614-616
    • Sato, A.1    Imaizumi, M.2    Koizumi, Y.3    Obara, Y.4    Nakai, H.5    Noro, T.6
  • 15
    • 20044381309 scopus 로고    scopus 로고
    • Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1
    • Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005; 37: 613-619.
    • (2005) Nat Genet , vol.37 , pp. 613-619
    • Li, Z.1    Godinho, F.J.2    Klusmann, J.H.3    Garriga-Canut, M.4    Yu, C.5    Orkin, S.H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.